Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ ADXS opened at $0.54 on Wednesday. The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.74. The company has a market cap of $5.81 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. Ayala Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.95.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.